# SCIENTIFIC **REPORTS**

Received: 30 April 2018 Accepted: 25 September 2018 Published online: 24 October 2018

## **OPEN** Acupuncture reduces the time from extubation to 'ready for discharge' from the post anaesthesia care unit: results from the randomised controlled AcuARP trial

J. Fleckenstein 1,2, P. Baeumler<sup>1</sup>, C. Gurschler<sup>1</sup>, T. Weissenbacher<sup>3</sup>, T. Annecke<sup>1,4</sup>, T. Geisenberger<sup>1,5</sup> & D. Irnich<sup>1</sup>

Acupuncture may improve peri-operative care as it reduces post-operative symptoms, such as pain, nausea and vomiting, or sedation. This patient-assessor blinded, randomised trial in 75 women undergoing gynaecologic laparoscopy evaluated the effects of acupuncture combined with a standardised anaesthetic regimen (ACU) on post-anaesthetic recovery, when compared to acupressure (APU) or standard anaesthesia alone (CON). Main outcome measure was the time from extubation to 'ready for discharge' from recovery as assessed by validated questionnaires. The main outcome differed significantly between groups (p = 0.013). Median time to ready for discharge in the ACU group (30 (IQR: 24–41) min) was 16 minutes (35%) shorter than in the CON group (46 (36–64) min; p = 0.015) and tended to be shorter than in the APU group (43 (31–58) min; p = 0.08). Compared to CON (p = 0.029), median time to extubation was approximately 7 minutes shorter in both, the ACU and the APU group. No acupuncture or acupressure-related side-effects could be observed. A difference in time to recovery of 16 minutes compared to standard alone can be considered clinically relevant. Thus, results of this study encourage the application of acupuncture in gynaecological laparoscopy as it improves postanaesthetic recovery.

Modern surgery management demands for an increasing operating room turnover and more ambulatory surgeries. In order to meet these challenges post anaesthetic recovery needs to be optimized. To enhance recovery, it is recommended to prevent or minimize the occurrence of pain, post-operative nausea and vomiting (PONV), paralytic ileus, fatigue and sleep disturbances<sup>1,2</sup>. Also, patients should arrive in the post anaesthesia care unit (PACU) the least sedated as possible in order to reduce the period at which they are vulnerable to side effects of anaesthesia<sup>3</sup>. Acupuncture seems a promising non-medical complementary treatment option to minimize important factors that impede post anaesthetic recovery<sup>4</sup>.

There is substantial evidence provided by systematic reviews for the effectiveness of acupuncture in reducing post-operative pain, cumulative opioid consumption, opioid related side effects as well as pre-operative anxiety<sup>5-8</sup>. It was also suggested to introduce acupuncture and related techniques for treatment and prophylaxis of post-operative nausea and vomiting in routine clinical practice in combination with, or as an alternative to, conventional antiemetics. This is confirmed by an up to date Cochrane review showing no difference between PC6 acupuncture point stimulation and antiemetic drugs to prevent PONV<sup>9</sup>. Accordingly the use of acupuncture is

<sup>1</sup>Department of Anaesthesiology, Ludwig-Maximilians University (LMU), Marchioninistraße 15, D-81377, Munich, Germany. <sup>2</sup>Department of Traditional Chinese Medicine/Acupuncture, Institute of Complementary Medicine IKOM, University of Bern, Personalhaus 4, Inselspital, CH-3010, Bern, Switzerland. <sup>3</sup>Department of Obstetrics and Gynaecology, Ludwig-Maximillians-University (LMU) Hospital, Maistraße 11, D-80337, Munich, Germany. <sup>4</sup>Department of Anaesthesiology and Intensive Care, University Hospital of Cologne, Uniklinik Köln, D-50924, Cologne, Germany. <sup>5</sup>Department of Anaesthesiology, Ospidal Engiadina Bassa, Via da l'Ospidal 280, CH-7550, Scuol, Switzerland. Correspondence and requests for materials should be addressed to J.F. (email: johannes.fleckenstein@ ikom.unibe.ch)

Inclusion Criteria	General Exclusion Criteria	Indication-specific Exclusion Criteria
<ul> <li>Age 18+</li> <li>Females scheduled for laparoscopic surgery of uterus, adnexa or ovaries</li> <li>American Society of Anaesthesiologists (ASA)-score ≤2</li> <li>Ability to follow study instructions and likely to attend and complete all required visits</li> <li>Written informed consent</li> </ul>	<ul> <li>Subject without legal capacity</li> <li>Subject who is unable to understand the nature, scope, significance and consequences of this clinical trial</li> <li>Simultaneously participation in another clinical trial or participation in any clinical trial involving administration of acupuncture within 30 days prior to inclusion</li> <li>Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the trial results, or may interfere with the subject's participation in this clinical trial</li> <li>Known or persistent abuse of medication, drugs or alcohol</li> <li>Current or planned pregnancy or nursing women</li> <li>Females of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration</li> </ul>	<ul> <li>Surgery within the last three months</li> <li>Chronic pain &gt; three months</li> <li>Continuous analgesic medication with opioids longer than three day</li> <li>Massive degenerative diseases</li> <li>Pre-treatment with acupuncture or trigger point injection within the last two months</li> </ul>

Table 1. Inclusion and Exclusion Criteria.

generally recommended in the consensus guidelines for the management of PONV by the Society for Ambulatory Anaesthesia<sup>10</sup>.

Based on this evidence we hypothesized that acupuncture may accelerate the time from extubation to 'ready for discharge' from the PACU, this being considered a meaningful indicator of post-anaesthetic recovery. In addition, this study investigated whether specific effects related to penetration of the skin would render press needle acupuncture superior to acupressure with non-penetrating press plasters<sup>11</sup>.

#### **Patients and Methods**

**Study Design.** This single-centre, patient-assessor blinded, randomised controlled study compared the effect of press needle acupuncture (ACU) and press plaster acupressure (APU) versus no treatment (CON) on post-operative recovery in a standard anaesthetic setting of programmed gynaecologic laparoscopic surgeries. Main outcome measure was the time from extubation to 'ready for discharge' from the PACU. Analysis of all records was performed by blinded assessors. The total follow-up period per patient was at least two days. The study took place at the Department of Gynaecology, Ludwig-Maximilians-University, Munich, Germany. The study was approved by the Ethics Committee of the University of Munich, Germany (reference 009–12) and is in agreement with the Declaration of Helsinki (Version Fortaleza 2012). Trial registration is NCT01816386. The protocol has previously been published<sup>11</sup>. The following paragraphs describe the study methods in brief.

**Patients.** Female patients scheduled for laparoscopic surgery of the uterus, the adnexa or the ovaries with an ASA-score  $\leq 2$  were screened for this study. Patients were included after signing written informed consent. For inclusion and exclusion criteria please refer to Table 1.

**Randomised treatment allocation, blinding and sample-size estimation.** Patients were informed, both orally and in writing, that this study would distinguish two forms of interventions (APU and ACU)<sup>12</sup>, and about the possibility of 33% to be allocated to a control group, where they would receive the same anaesthetic care and attention by the study team as all other participants.

Following written informed consent, patients were randomly assigned to either ACU, CON or APU by using the internet based randomization software RANDOULETTE<sup>®</sup> (Institute of Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-University of Munich). Blinding of patients and assessors was ensured by using press needles & press plasters<sup>12</sup>. Patients in the control group could not be blinded.

The sample size of 75 patients was estimated on the basis of a supposed small to medium effect (Cohen's d = 0.4) on post-operative recovery, an alpha-error of 5%, a power of 80% and a drop-out rate of 15% using G\*Power (Version 3.1.3, University of Düsseldorf, Germany)<sup>11</sup>. The estimated time to recovery following gynae-cologic laparoscopy in our clinic has been observed to range from 45 to 60 minutes, similar to published data resulting from mini cholecystectomy<sup>13</sup>. Shortening this time by 25% (i.e. 11 to 15 minutes) seems to be clinically meaningful<sup>14</sup>.

**Anaesthetic Proceedings.** The anaesthetic procurements were standardised and based on general recommendations and guidelines of the German Society of Anaesthesiology (DGAI) and clinic standards, and have previously been described in depth<sup>11</sup>. Opioids and propofol were administered by Target Controlled Infusion (TCI; Fresenius-Kabi Orchestra<sup>®</sup> Base Primea syringe pumps, Fresenius Kabi Group, Bad Homburg, Germany). The target effect-site concentrations for the induction (maintenance) of anaesthesia were 0.2–0.4 (0.12–0.22) ng/ ml sufentanyl and 3.0 to 9.0 (3.0–4.0) µg/ml propofol.

All patients received metamizol 2.5 g intra-venous (i.v.)-infusions during the last 30 minutes of the surgery to prevent post-operative pain, dexamethasone 8 mg i.v. (after induction) to prevent PONV and ranitidine 50 mg i.v. (after induction) for prevention of gastric stress ulcer.

Post-operative pain therapy included metamizol (4\*1.25 g/day, 6 hours interval) on demand. In case of nausea and vomiting or shivering patients were treated according to the clinical standard.

**Interventions.** At the time of the pre-anaesthetic visit, 12–24 hours prior to surgery, patients in the intervention groups received a standardised treatment with either 12 press needles (ACU; sharp tip; 0.2 mm × 1.5 mm) or 12 press plasters (APU; blunt knob; both Seirin New Pyonex<sup>®</sup>, Seirin Corp., Shizuoka City, Japan) at GV26, a

point described to resolve states of sedation and collapse<sup>15,16</sup> and 6 acupuncture points which have been proposed to relief pain and strengthen the constitution, i.e. CV17 (on the middle body line), and bilateral LI4, HT7, LR3, ST36 and PC6)<sup>11</sup>. Deqi response is usually not elicited when applying press needles, and was consequently not required. Needles or plasters were left in place for 72–96 hours depending on the patient's discharge from the hospital (earliest 48 hours after surgery), covering the whole perioperative period. Treatments were performed by three acupuncturists with at least 120 hours acupuncture training. (A-Diploma standard of the German Medical Acupuncture Association DÄGfA).

Patients were instructed to press the needles or plasters as often as wanted, especially when suffering from anxiety, pain or nausea and vomiting. Three daily visits were established to guarantee at least three stimulations per day. During emergence, i.e. starting with the end of anaesthetic drugs, the trial team was required to stimulate at the acupuncture point GV26.

The control group underwent the same standard anaesthetic procedure, received the same amount of peri-operative visits, and the same empathy and motivation by the study team.

**Blinding procedure.** In this study a patient and assessor blind situation regarding the use of press needles versus press plasters was achieved. Neither patients nor examiners were able to distinguish between these two interventions<sup>12</sup>, as both parties do not know if a sharp needle (acupuncture) or a blunt knob (acupressure) was located below the plaster<sup>11</sup>. However the patients in the control group could not be blinded, as they were aware of not receiving an additional treatment. Also assessors could not be blinded with regard to the control group, as patients did not carry plasters.

**Outcome measures.** Main outcome measure. The main outcome measure, was the time from extubation of the trachea to 'ready for discharge' from the PACU as assessed by three independent recovery scores (Aldrete<sup>17</sup>, Post Anaesthetic Discharge Scoring System<sup>18</sup>, in-house score for outpatients; for details please refer to the study protocol)<sup>11</sup>. All scores consist of five items regarding different postoperative physiologic states of the patient, which are graded from 0 to 2. A summated score of 9 to 10 indicates that the patient is ready for discharge. When fulfilling all scores, the patient was graded as ready for discharge.

*Secondary outcome measures.* Secondary outcomes have been previously been described<sup>11</sup>. Acupuncture-related outcomes included pre-operative anxiety, depth of sedation (bispectral index; BIS), reaction times during emergence, time to extubation, post-operative analgesic consumption and pain intensity, and the occurrence of anaesthesia-related side effects.

*Statistical analysis.* Data entry was carried out twice. Analysis was performed with the SPSS statistical software system (SPSS Inc., Chicago, IL; version 23.0). Fisher test was used to compare binary outcomes between the control and the intervention groups. Metric-variables were assessed for normal-distribution by Kolmogorov-Smirnov-Test. For normally distributed variables, the mean and standard deviation (SD) were calculated for descriptive analyses, and groups were compared by an analysis of variance (ANOVA). The unpaired t-Test was used for post-hoc pairwise comparisons. Influence of group x time of the state anxiety was assessed by ANOVA for repeated measures with group as between subject factor. In case of a non-normal distribution, non-parametric analyses were performed with descriptive statistics given as median (M) and interquartile-range (IQR). Kruskal-Wallis-Test was used for intergroup comparisons. Dunn's Test was used for post-hoc pairwise group comparisons.

In order to address the bias possibly induced by unequal surgery durations, a sensitivity analysis excluding cases with extremely short, extremely long or missing surgery times. Extreme values were identified from the graphical display of individual surgery times per group.

#### Results

Seventy-five women (age (mean (SD)) 44 (12) years, height 167 (7) cm, weight (median (IQR)) 65 kg (58–78), pain intensity at admission 0.1 (0.0–0.3) cm on a 10 cm visual analogue scale, VAS) were included and randomised into the study. Four patients dropped out of the study; two due to a conversion of the surgery to an open procedure (n = 2), one patient claimed for midazolam instead of continuing in the study, and one patient received midazolam accidentally (Fig. 1). Surgical sites were adnexa 56%, uterus 37% or both 7%. Patient characteristics were similar in the three study groups with the exception of body weight that was highest in the ACU group (Table 2).

The main outcome parameter, time from extubation to 'ready for discharge' from the PACU was significantly decreased in the ACU group (median (IQR) 30 (24–41) min; Kruskal-Wallis-Test p = 0.013) when compared to the CON group (46 (36–64) min; post-hoc Dunn's Test p = 0.005) and the APU group (43 (31–58) min; post-hoc Dunn's Test p = 0.028; see Table 3 and Fig. 2). The median time to ready for discharge from the PACU in the ACU group was 35% less than in the CON group, and 29% less than in the APU group to fulfil all the discharge criteria. There were no significant differences in the time to extubation as calculated by the TCI pumps (see Table 4).

Regarding pre-operative anxiety, there were no differences in state and trait anxiety between groups at baseline, nor at admission in the morning of the day of surgery or directly before induction (see Table 4). Repeated measures ANOVA of state anxiety (time  $\times$  group; 3  $\times$  3) revealed a trend towards an interaction between time and intervention group (p=0.067). Changes in state anxiety from baseline at the time point of induction showed clinically remarkable differences when comparing the CON (mean (SD) 9 (8)) to the ACU (5 (7)), or the APU group (3 (8); Fig. 3).





The BIS index indicated significant differences between groups with regard to sedation at induction of an assthesia (p = 0.029), and when turning off the TCI (p = 0.020). Post-hoc tests revealed, that at induction of an assthesia, patients in the ACU group had lower BIS when compared to the CON group (median (IQR) 97 (96–98) vs 98 (98–98); p = 0.008). When turning off the TCI, patients in both the ACU (38 (31–50); p = 0.015) and the APU group (42 (27–50); p = 0.016) showed significantly higher BIS scores when compared to the CON group (32 (24–39); Table 4).

In addition, there was a significant shorter time between the stop of the TCI and extubation in the ACU (median (IQR) 12 (7–22) min; p = 0.028) and the APU group (13 (9–20) min; p = 0.017) when compared to the CON group (19 (14–26) min; Kruskal-Wallis-Test p = 0.029; Table 3).

No differences of anaesthetic drugs or depth of anaesthesia following 5 minutes after induction between groups could be observed (Table 4). The median total amount of sufentanyl was 44 (IQR: 40–49) µg and of propofol 1197 (IQR: 975–1594) mg with no differences between groups. However, duration of surgery differed significantly between groups (p = 0.035 Kruskal-Wallis-Test). Pairwise group comparisons revealed significantly shorter surgery time in the CON group (median (IQR) 56 (44–71)) than in the APU (73 (55–115); p = 0.028) and ACU group (85 (52–107); p = 0.023). Time from induction to turning off the TCI was also different between groups (p = 0.048; Kruskal-Wallis-Test) with significantly shorter times in the CON group (92 (84–103) than in the APU group (105 (95–159); p = 0.015).

To address possible bias introduced by unequal surgery durations, a sensitivity analysis excluding cases with extremely short, extremely long or missing surgery times was performed (Fig. 4). The overall group difference in time from extubation to 'ready for discharge' remained significant (Kruskal-Wallis-Test p = 0.015). Median time in the ACU group remained significantly shorter (13.5 min) than in the control group (p = 0.004), but the time difference to the APU group did not meet statistical significance (p = 0.108). The overall group comparison

		Total (n = 71)	APU (n = 24)	CON (n = 24)	ACU $(n=23)$	p-value
Age (years), range		19–72	26-69	26-72	19–71	<sup>a</sup> 0.765
Height (cm), mean (SD)		167.2 (7.0)	169.4 (7.1)	167.0 (6.9)	165.0 (6.7)	<sup>a</sup> 0.102
Weight (kg), M (IQR	<u>()</u>	65.0 (58.0-78.0)	71.5 (61.5-81.5)	62.5 (58.3-70.5)	63.5# (55.0-72.0)	<sup>b</sup> 0.031*
	Single	33 (46.5)	9 (37.5)	11 (45.8)	13 (56.5)	
Circil status $n(0)$	Married	28 (39.4)	11 (45.8)	11 (45.8)	6 (26.1)	
Civil status II (70)	Widowed	2 (2.8)	1 (4.2)	0 (0.00)	1 (4.3)	]
	Divorced	8 (11.3)	3 (12.5)	2 (8.3)	3 (13.0)	
	Protestant	8 (11.4)	2 (8.7)	1 (4.2)	5 (21.7)	
$\mathbf{D}$ aligner $\mathbf{n}$ (0()	Catholic	39 (55.7)	13 (56.5)	14 (58.3)	12 (52.2)	
Religion n (%)	Islam	4 (5.7)	2 (8.7)	2 (8.3)	0 (0.0)	1
	Others/none	19 (27.1)	6 (26.1)	7 (29.2)	6 (26.1)	1
	Main school	6 (8.5)	4 (16.7)	2 (8.3)	0 (0.00)	
Education $n(0)$	Secondary school	21 (29.6)	7 (29.1)	4 (16.7)	10 (43.5)	
Education II (%)	A-level	11 (15.5)	2 (8.3)	6 (25.0)	3 (13.0)	
	College degree	33 (46.5)	11 (45.8)	12 (50.0)	10 (43.5)	
	Student	4 (5.7)	1 (4.2)	1 (4.2)	2 (9.1)	
	Blue collar worker	2 (2.9)	2 (8.3)	0 (0.00)	0 (0.0)	
	Employee	44 (62.9)	13 (54.2)	17 (70.8)	14 (63.6)	
Dur frazier w (0/)	Public official	2 (2.9)	1 (4.2)	0 (0.0)	1 (4.5)	
Profession II (%)	Retired	3 (4.3)	0 (0.0)	2 (8.3)	1 (4.5)	
	House wife	6 (8.6)	4 (16.7)	2 (8.3)	0 (0.0)	
	Unemployed	2 (2.9)	2 (8.3)	0 (0.0)	0 (0.0)	1
	Self-employed	7 (10.0)	1 (4.2)	2 (8.3)	4 (18.2)	
	Uterus	26 (36.6)	11 (45.8)	7 (29.2)	8 (34.8)	
Type of surgery	Adnexa	40 (56.3)	13 (54.2)	14 (58.3)	13 (56.5)	1
	Uterus & Andexa	5 (7.0)	0 (0.0)	3 (12.5)	2 (8.7)	
Pain at admission (VAS, 0–10 cm), M (IQR)		0.1 (0.0-0.3)	0.1 (0.0-0.29)	0.1 (0.0-0.65)	0.0 (0.0-0.2)	0.395

**Table 2.** Patients demographic characteristics. APU: press plaster acupressure, CON: control, ACU: press needle acupuncture, n: case number, SD: standard deviation, M: median, IQR: interquartilerange, <sup>a</sup>ANOVA, <sup>b</sup>Kruskal-Wallis-Test, \*significant overall group difference on an alpha level of 5%, \*significantly different from the APU group on an alpha level of 5%, post-hoc *pairwise group* comparisons were performed by Dunn's Test.

	Total (n = 71)	APU (n = 24)	CON (n = 24)	ACU (n = 23)	p-value				
Operating theater									
Time TCL off to PIS 70 (min)	n	69	22	24	23				
	M (IQR)	10.0 (6.5–16.0)	10.0 (5.0–11.3)	12.5 (9.0–17.8)	8.0 (6.0–19.0)	0.069			
Time TCIeff to entrylation (min)	n	71	24	24	23				
Time (Cloir to extubation (min)	M (IQR)	16.0 (10.0-22.0)	13.0 (9.3-20.0)#	19.0 (14.0-25.8)	12.0 (7.0-22.0)#	0.029*			
	n	64	23	21	20				
Time from induction of anestnesia to suture (min)	M (IQR)	107.0 (97.3–145.0)	112.0 (101.0-155.0)	100.0 (91.5-113.0)	128.5 (86.5–150.5)	0.114			
Main outcome									
Time to 'and de for discharge' from DACU (min)	n	71	24	24	23				
Time to ready for discharge from PACO (mm)	M (IQR)	40.0 (28.0-55.0)	42.5 (31.0-58.0)	46.0 (36.0-63.8)	30.0 (24.0-41.0)#,§	0.013*			

**Table 3.** Anesthetic recovery period. APU: press plaster acupressure, CON: control, ACU: press needle acupuncture, n: case number, M: median, IQR: interquartilerange, min<sup>-1</sup>: per minute, mmHg: millimeters of mercury, BIS: bispectral index, min: minute(s), TCIoff: stop of target controlled infusion, O<sub>2</sub>: Oxygen, PACU: post-anaesthesia care unit, \*significant on an alpha level of 5% according to Kruskal-Wallis-Test, \*significantly different from APU group. Post-hoc pairwise group comparisons were performed by Dunn's Test.

in time to extubation remained significant (p = 0.037), and pairwise comparisons showed a shorter times in the ACU (p = 0.025) and APU group (p = 0.027) when compared to CON group.

There were no group differences in vital signs at any time and in pain intensity during the whole post-operative period (Table 4 and Supplementary Table 1). Groups neither differed in regard to total analgesic consumption (in total 52 consumptions; Table 4).



**Figure 2.** Times to recovery. The figure indicates the time from extubation to ready for discharge from the PACU, with acupuncture showing the fastest time to full recovery. The figure shows boxplots (with median and IQRs) as well as outliers (circles). Between groups analysis revealed significant differences (Kruskal-Wallis p = 0.013). P-values are given for the post-hoc pairwise comparisons as performed by Dunn's test. APU: press plaster acupressure, CON: control, ACU: press needle acupuncture.

There was a lower number of patients suffering from PONV in the APU and the ACU group than in the CON group (Table 4). Eleven patients in the CON group suffered from nausea and seven of them also from vomiting, whereas eight patients in the APU group and six patients in the ACU group, suffered from nausea of which three and one also suffered from vomiting, respectively. The incidence of vomiting was significantly reduced in the ACU when compared to the CON group (Fisher-Test p = 0.018).

There were no severe side effects caused by one of the study interventions. One patient in the ACU group experienced a minor adverse event in terms of slight redness at the needling site (GV 26).

#### Discussion

The results of the AcuARP trial show that acupuncture applied by press needles can be effective in improving patients' post-anaesthetic recovery. Median time from extubation to 'ready for discharge' from the PACU was 16 min shorter in ACU group than in the control group. In contrast, acupressure did not substantially affect the time from extubation to 'ready for discharge'. This suggests specific effects elicited by the needle stimulus which render acupuncture superior over acupressure. This may be related to the overall stronger sensory input elicited by the penetrating needling stimulus when compared to non-penetrating pressure alone. Penetrating needles mechanically stimulate cells followed by a release of endogenous substances, that have been shown to activate neural afferents (A and C fibres)<sup>19</sup>, a way of action which may not be achieved by simple non-penetrating pressure.

To our knowledge, this is the first study evaluating the time between extubation and discharge from the PACU by means of standardised validated questionnaires<sup>11</sup>. There are hints from other studies using different outcome parameter for evaluating post anaesthetic recovery. Meta-analytic evidence from 7 studies with 540 patients indicates that acupuncture is efficient and safe for improving recovery after colorectal cancer surgery, namely time to first flatus and time to first defecation<sup>20</sup>. Additionally, in patients undergoing ophthalmic surgeries, acupuncture was shown to reduce time to spontaneous eye opening, time to extubation, and time to follow commands when compared to sham or control<sup>21</sup>. To prevent adverse events from electrical currents, the use of bipolar laparoscopic systems is preferable. When choosing monopolar systems, one should take a sufficient distance to the needles into account, and the current should be derived in the opposite direction. In this study no burns or electricity related adverse events could be observed.

Further observations in our study are also indicative for the beneficial effects of acupuncture during the post-operative recovery period. Stimulation at the acupuncture point GV26 seems particularly effective in promoting awakening independent of needle specific effects. Both, patients in the ACU and the APU group, could be extubated 6–7 minutes earlier after turning off the TCI-pump than patients in the CON group. This observation is in line with results from the trial in patients undergoing ophthalmic surgery mentioned above, as well as with animal experiments in snapping turtles<sup>15</sup> and in rabbits<sup>22</sup>. Acupuncture is supposed to activate noradrenergic neurotransmission in the brain which in turn reduces the central nervous depressive activity of anaesthetics<sup>22</sup>. However, the faster awakening in the two intervention groups could also be due to the fact that the anaesthetic state was already less deep at the time-point when anaesthetic infusion was stopped; as indicated by the BIS.

The increase of state anxiety during the period from admission to induction of anaesthesia was less pronounced in patients receiving acupuncture or acupressure than in patients in the control group (see Fig. 3). BIS scores indicated a trend towards an accelerated sedation and an earlier regain of consciousness when receiving acupuncture or acupressure. The observed effects on anxiety are in line with previously reported effects of ear

		Total (n = 71)	APU (n = 24)	CON (n = 24)	ACU (n = 23)	p-value			
Pre-operative anxiety									
Baseline									
STAI State	n	66	22	22	22	0.482			
51AI-5uute	mean (SD)	$42.5\pm9.0$	$42.2\pm11.2$	$41.0\pm8.0$	$44.3\pm7.4$				
STAL Trait	n	68	22	23	23	0.075			
51AI-11uu	mean (SD)	$37.0\pm9.1$	$39.1\pm9.0$	$33.5\pm7.1$	$38.5\pm10.2$				
Morning of surgery									
STAL State	n	65	19	23	23	0.788			
51711-5 <i>uuc</i>	mean (SD)	$45.0\pm10.7$	$43.9\pm12.7$	$46.2\pm11.9$	$44.8\pm7.6$				
STAL Trait	n	64	20	23	21	0.267			
51711-17444	mean (SD)	$37.2\pm9.3$	$39.5\pm9.6$	$34.9\pm7.7$	$37.4\pm10.4$				
Prior to induction									
STAI-State	n	71	24	24	23	0.196			
	mean (SD)	$48.3 \pm 11.4$	$45.0\pm12.2$	$50.8\pm12.7$	$49.2\pm8.5$				
STAI-Trait	n	70	24	23	23	0.379			
	mean (SD)	36.3 ± 9.9	$37.1\pm9.6$	$33.9\pm7.5$	$37.7\pm12.1$				
Induction of anaesthesia				1					
BIS at induction	n	71	24	24	23	0.029*			
	M (IQR)	98.0 (97.0-98.0)	98.0 (97.0-98.0)	98.0 (98.0-98.0)	97.0 (96.0-98.0)*				
BIS at 5 minutes after	n	71	24	24	23	0.78			
induction	M (IQR)	43.0 (36.0-56.0)	44.5 (34.0-58.3)	47.0 (35.5–56.0)	41.0 (37.0-49.0)				
Sufentanyl at intubation	n	68	23	23	22	0.54			
(µg)	M (IQR)	26.3 (21.1-33.5)	24.2 (20.5-30.8)	26.8 (21.1-34.0)	28.0 (21.2-34.3)				
Propofol at intubation (mg)	n	68	23	23	22	0.891			
	M (IQR)	261.0 (198.0-299.3)	263.0 (214.0-294.0)	260.0 (218.0-293.0)	243.5 (184.8-327.8)				
Mivacurium at intubation	n	55	21	17	17	0.533			
(mg)	M (IQR)	13.8 (12.0–16.0)	14.0 (12.1–16.0)	13.0 (12.0–14.8)	12.8 (11.5–17.7)				
Atracurium at intubation	n	16	3	7	6	0.805			
(mg)	M (IQR)	30.0 (30.0-30.0)	30.0 (30.0-30.0)	30.0 (30.0-30.0)	30.0 (27.5-42.5)				
Effect Site Conc.	n	71	24	24	23	0.414			
sufentanyl <sub>BIS50</sub>	M (IQR)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.4 (0.3–0.5)	0.3 (0.3–0.5)				
Effect Site Conc. propofolaisco	n	70	24	23	23	0.925			
	M (IQR)	7.0 (5.9–7.9)	7.0 (6.0–7.5)	7.0 (5.8–8.0)	6.7 (5.8–7.8)				
Time from induction to	n	70	23	24	23	0.799			
cut (min)	M (IQR)	42.0 (36.0-50.0)	39.0 (36.0-53.0)	45.5 (37.0-54.0)	42.0 (36.0-48.0)				
End of anaesthesia		1							
BIS at TCIoff	n	71	24	24	23	0.020*			
	M (IQR)	37.0 (27.0-44.0)	41.5 (27.3-49.8)*	31.5 (24.0-38.8)	38.0 (31.0-50.0)#				
BIS at first breathing	n	71	24	24	23	0.664			
	M (IQR)	70.0 (57.0–77.0)	70.0 (55.5–76.0)	72.5 (54.3-83.0)	68.0 (57.0-74.0)				
BIS at extuabtion	n	71	24	24	23	0.222			
	M (IQR)	80.0 (75.0-84.0)	81.5 (76.3-83.8)	83.0 (75.5–87.3)	76.0 (74.0-82.0)				
Effect site conc.	n	71	24	24	23	0.072			
Sufentanyi <sub>TCloff</sub> (ng/ml)	M (IQR)	0.1 (0.1-0.2)	0.1 (0.1-0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)				
Effect site conc.Propofol <sub>TCloff</sub>	n	71	24	24	23	0.951			
(µg/mi)	M (IQR)	2.8 (2.2–3.5)	2.7 (2.1-3.5)	2.9 (2.1–3.5)	2.6 (2.3–3.5)				
Total sufentanyl (µg)	n	71	24	24	23	0.615			
······································	M (IQR)	43.8 (39.8-48.7)	46.5 (40.0-52.9)	44.3 (39.1-46.3)	42.5 (38.8-47.7)				
Total propofol (mg)	<i>n</i>	69	22	24	23	0.079			
	M (IQR)	1197.0 (975.0–1594.0)	1300.0 (1092.8–1793.0)	1109.0 (930.5–1333.5)	1251.0 (932.0-1598.0)				
Total mivacurium (mg)	n	55	21	17	17	0.233			
	M (IQR)	30.0 (26.0–36.0)	29.0 (25.0–35.0)	26.6 (24.5–33.0)	30.5 (27.0–45.0)	0.077			
Total atracurium (mg)	<i>n</i>		3	7	6	0.805			
	M (IQR)	30.0 (30.0-30.0)	30.0 (30.0-30.0)	30.0 (30.0-30.0)	30.0 (27.5-42.5)				
Time to awakening	n	/1	24	24	23	0.098			
sujenunyi <sub>TCloff</sub> (mm)	M (IQR)	11.0 (1.0-22.0)	/.0 (0.0–18.8)	16.0 (5.5–29.0)	11.0 (0.0–23.0)				
Continued									

<table-container><table-container><math><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></math></table-container></table-container>			·	Total (n=71)	APU (n = 24)	CON(n=24)	ACU (n = 23)	p-value			
<table-container><table-container><math><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></math></table-container></table-container>	Time to awakening	n		71	24	24	23	0.281			
<table-container><table-container><math><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></math></table-container></table-container>	propofol <sub>TCIoff</sub> (min)	M (IQR	)	9.0 (6.0–15.0)	8.0 (6.3–13.0)	8.0 (6.0-16.8)	12.0 (6.0–18.0)				
<table-container><table-row><math><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></math></table-row></table-container>	Effect site conc.	n		71	24	24	23	0.997			
<table-container><table-container><math><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></math></table-container></table-container>	sufentanyl <sub>Extubation</sub> (ng/ml)	M (IQR	)	0.1 (0.1-0.1)	0.1 (0.1-0.1)	0.1 (0.1-0.1)	0.1 (0.1-0.1)				
<table-container><math><table-row><table-container>implomphatmaketTargeneration</table-container></table-row></math></table-container>	Effect Site Conc.	n		70	24	24	22	0.136			
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	propofol <sub>Extubation</sub> (µg/ml)	M (IQR	)	1.1 (0.9–1.3)	1.0 (0.9–1.3)	1.0 (0.8–1.1)	1.1 (1.0–1.4)				
<table-container><table-row><math><table-row>Phy-PartmatrixPartmatri</table-row></math></table-row></table-container>	Time from induction to	n		71	24	24	23	0.048*			
<table-container>number 3<math>         - <math>         - <math> </math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></math></table-container>	TCIoff (min)	M (IQR	)	100.0 (84.0-138.0)	105.0 (95.0-158.5)#	91.5 (84.0-103.3)	123.0 (75.0-143.0)				
<table-container>Number of the sector of the</table-container>	Duration of aurgary (min)	n		63	22	21	20	0.035*			
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	Duration of surgery (min)	M (IQR	)	65.0 (49.0-95.0)	72.5 (55.0-114.5)#	56.0 (44.0-70.5)	84.5 (52.0-106.8)#				
<table-container><table-container><table-row><math><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></math></table-row></table-container></table-container>	Pain (VAS, 0–10 cm)				·						
<table-container>          bind         Impact of the sector of th</table-container>	End of DACU	n		68	24	23	21	0.87			
hereIPPP	End of PACO	M (IQR	)	1.0 (0.0-2.0)	1.0 (0.0-2.0)	1.0 (0.0-2.0)	1.0 (1.0-2.0)				
<table-container>nh part of the sector of th</table-container>	( h most summer	n		70	23	24	23	0.365			
hereImage <th< td=""><td>6 n post-surgery</td><td>M (IQR</td><td>)</td><td>2.1 (0.7-3.1)</td><td>2.3 (0.6-4.1)</td><td>2.2 (0.8-4.1)</td><td>1.7 (0.5–2.7)</td><td></td></th<>	6 n post-surgery	M (IQR	)	2.1 (0.7-3.1)	2.3 (0.6-4.1)	2.2 (0.8-4.1)	1.7 (0.5–2.7)				
<table-container>M10M10I 10.0-2.7.I 10.0-3.1.I 9.09.3.1.I 2.05.2.1.I 0.0A1 HamIII&lt;</table-container>	11 000	n		71	24	24	23	0.335			
<table-container>networknetworksquares</table-container>	<i>u</i> 1 8	M (IQR	)	1.3 (0.6–2.7)	1.1 (0.3–3.1)	1.9 (0.9-3.1)	1.2 (0.5–2.1)				
<table-container>          Inform         <thinform< th=""> <thinform< th=""> <thinform< <="" td=""><td>11 1 1 0 0</td><td>n</td><td></td><td>68</td><td>24</td><td>21</td><td>23</td><td>0.712</td></thinform<></thinform<></thinform<></table-container>	11 1 1 0 0	n		68	24	21	23	0.712			
<table-container><math>120^{\circm}</math><math>120^{\circ}</math><math>10</math> (0.3-2.0)<math>120</math><math>10</math> (0.4-2.3)<math>1.0</math> (0.5)<math>10</math><math>2^{20^{\circ}}</math><math>10^{\circ}</math><math>10</math> (0.3-2.0)<math>10</math> (0.4-2.3)<math>10</math> (0.5)<math>10</math><math>10^{\circ}</math><math>2^{20^{\circ}}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math><math>10^{\circ}</math>&lt;</table-container>		M (IQR	)	1.1 (0.4–2.7)	0.7 (0.1-3.2)	1.7 (0.7–2.9)	1.3 (0.5–1.9)				
<table-container><math>d1.0^{0}</math><math>M(Q_R)</math><math>10(0,3-2.0)</math><math>07(0,1-2.0)</math><math>13(0,4-2.3)</math><math>11(0,5-1.9)</math><math>0.607</math><math>d^2 8^{ab}</math><math>n</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><math>\zeta</math><t< td=""><td>11 2000</td><td>n</td><td></td><td>69</td><td>24</td><td>22</td><td>23</td><td>0.346</td></t<></table-container>	11 2000	n		69	24	22	23	0.346			
A28°         n         21         23         0.000           A21°         MQU<**	a1 20 <sup>-1</sup>	M (IQR	)	1.0 (0.3-2.2)	0.7 (0.1-2.0)	1.3 (0.4–2.3)	1.1 (0.5–1.9)				
dl QR         p         05 (0.1-17)         03 (0.0-2.6)         1.0 (0.2-1.8)         0.6 (0.2-1.2)         0.77           d 21 <sup>des</sup> R         0         0.0 (0.7)         22 cm         18         0.6 (0.3-1.0)         0.77           d2 20 <sup>m</sup> R         0.6 (0.2-1.6)         0.5 (0.2-2.6)         0.6 (0.3-1.1)         0.5 (0.3-1.2)         0.5 (0.3-2.6)         0.6 (0.3-1.1)         0.5 (0.3-1.2)         0.5 (0.3-2.6)         0.5 (0.3-1.2)         0.5 (0.3-2.6)         0.5 (0.3-1.2)         0.5 (0.3-2.6)         0.5 (0.3-1.2)         0.5 (0.3-1.2)         0.5 (0.3-1.2)         0.5 (0.3-1.2)         0.5 (0.3-1.2)         0.5 (0.3-1.2)         0.5 (0.1.2)         0.5 (0.1.2)	10,000	n		68	24	21	23	0.697			
$A_{21}$ $P_{-}$ APP (P_{-} P_{-} P_{-	<i>a2</i> 8 <sup>88</sup>	M (IQR	)	0.5 (0.1–1.7)	0.3 (0.0-2.6)	1.0 (0.2–1.8)	0.6 (0.2–1.2)				
dl dd         M (dd         06 (0.2 - 1.6)         0.7 (0.0 - 1.5)         0.6 (0.2 - 1.6)         0.6 (0.3 - 1.1)         0.6 (0.3 - 1.1)           d 2 20"         M         -         0.3 (0.1 - 1.3)         0.3 (0.1 - 1.4)         0.5 (0.2 - 1.1)         0.5 (0.1 - 1.1)	10 4 400	n		60	22	18	20	0.737			
$d_2 20^{\circ}$ $n   V   V   V   V   V   V   V   V   V   $	a2 14°°	M (IQR	)	0.6 (0.2–1.6)	0.7 (0.0-1.5)	0.5 (0.2–2.6)	0.6 (0.3-1.1)				
d2.20°M(U)03 (0.1-1.2)03 (0.0-1.3)03 (0.1-1.4)0.5 (0.2-1.1)ParalieIntermediation of the second sec	10.0000	n		53	20	17	16	0.592			
ProteinProteinProvalue *CONCON (n = 24)ACU (n = 23)Produce versionAnalgesic consumption inV 45.6314.1700.0003 (13.04)1WHO3n (%)29 (40.85)8 (33.33)0.58112 (50.00)9 (39.13)0.561Total patientsn (%)3 (3 (46.48)9 (37.03)0.56112 (50.00)12 (52.17)0.701Analgesic consumption area (40.53)16 (17)100016 (25.03)13 (55.21)1.000Total patientsn (%)4 (5.33)16.17)100016 (25.03)13 (55.21)1.000Total patientsn (%)4 (5.33)16.01107.03)13 (55.21)1.000Total patientsn (%)2 (32.39)8 (3.33)0.6112 (50.00)9 (93.13)0.561WHO3n (%)3 (14.22)9 (37.50)1.00112 (50.00)9 (93.13)0.561WHO3n (%)3 (14.23)1.00112 (50.00)9 (39.13)0.561Total patientsn (%)3 (14.23)1.00114 (20.00)1.0011.001Number of patients in the trace trace the trace trace the trace tra	$d2 20^{33}$	M (IQR	)	0.3 (0.1–1.2)	0.3 (0.0-1.3)	0.3 (0.1–1.4)	0.5 (0.2–1.1)				
Analgesic consumption         Incline Information         Predict         <		Total (n	-71)	APU(n-24)	n-value vs CON	CON(n-24)	ACU(n - 23)	p-value			
Analges: consumption in VerticeWHO1n(%)4 (5a.3)1 (4.17)0 (0.00)1 (2.0.00)9 (3.0.1)0.5.1WHO3n(%)3 (4.6.4)9 (3.7.5)0.5611 (2.6.00)1 (2.5.17)0.72Analges: consumption #VerticeVerticeVerticeVerticeVerticeVerticeVerticeWHO3n (%)4 (0.6.7)1 (3.6.17)10.00(8.6.20)1.4.13.5.200.7.13.5.20Vertice <t< td=""><td colspan="11"><math display="block">\begin{array}{ c c c c c c c c c c c c c c c c c c c</math></td></t<>	$\begin{array}{ c c c c c c c c c c c c c c c c c c c$										
WHO1n (%)4 (c.5.0)1 (4.17)0 (0.00)3 (13.04)0WHO3n (%)29 (0.05)8 (0.33.0)0.381 (2 (0.00)9 (0.31.0)0.561Datal patientsn (%)3 (3 (4.17)0.5611 (5 (0.00)1 (2 (3.17)0.72Anagesic consumption after terreterreterreterreterreterreterre	Analgesic consumption in t	he PACU			1	1	1	r			
WHO3n (%)29 (40.85)8 (33.33)0.3812 (250.00)9 (31.31)0.561Total patientsn (%)3 (34.64)9 (37.50)0.5112 (50.00)12 (52.17)0.772Anlgesic consumption = transmission =	WHO1	n (%)	4 (5.63)	1 (4.17)		0 (0.00)	3 (13.04)				
Total patientsn (%)33 (4-A8)9 (37.50)0.56112 (50.00)12 (52.17)0.772Anagesic consumptiona universityVHO1n (%)4 (56.3)13 (54.17)10002 (8.33)12 (52.17)0.100VHO1n (%)4 (56.3)13 (54.17)1.0002 (8.33)1 (4.35)1.000Total patientsn (%)4 (56.3)1 (4.17)1.0002 (8.33)1 (3.65.2)0.371Output total patientsn (%)4 (56.3)1 (4.17)1.0002 (8.33)1 (3.65.2)0.3710.371Output total patientsn (%)2 (32.39)8 (3.33)5.611 (3.65.20)9 (39.13)0.561WHO1n (%)3 (32.29)9 (3.75.0)0.5611 (2.50.00)9 (39.13)0.561Output total patientsn (%)3 (3.23)1 (3.011 (2.50.00)9 (39.13)0.561Output total patientsn (%)3 (3.22.9)9 (3.75.0)0.5611 (2.50.00)9 (39.13)0.561Output total patientsn (%)3 (3.23)1 (3.011 (2.50.00)9 (39.13)0.5611 (2.50.00)9 (39.13)0.561NUMBER Colspan="6">Output total patientsn (%)3 (7.03)1 (3.011 (2.50.00)9 (39.13)0.5611 (3.50.00)1 (3.70.00)1 (3.70.00)1 (3.70.00)1 (3.70.00)1 (3.70.00)1 (3.70.00)1 (3.70.00)1 (3.70.00)1 (3.70.00)<	WHO3	n (%)	29 (40.85)	8 (33.33)	0.38	12 (50.00)	9 (39.13)	0.561			
Analgesic consumption affective         From Pacter           WHO1         n(%)         40(5.34)         13(4.17)         1.000         2(8.33)         1(4.3)         0.07           WhO3         n(%)         4(5.3)         14.17)         1.000         2(8.33)         1(4.3)         0.031           Total patients         n(%)         4(5.3)         164.83         0.547         17(70.83)         13(56.2)         0.371           Cmulative analgesic consumption         v         v         16(8)         3(3.3)         1(25.00)         9(39.13)         0.561           WHO3         n(%)         304.225         9(37.50)         0.561         12(50.00)         9(39.13)         0.561           WHO3         n(%)         304.225         9(37.50)         0.561         12(50.00)         9(39.13)         0.561           MHO4         n(%)         304.225         9(37.50)         0.561         12(50.00)         18(75.00)         18(75.00)         18(75.00)         18(75.00)         18(75.00)         18(75.00)         18(75.00)         10.00         100         100         100         100         100         100         100         100         100         100         100         100         100         100 <td>Total patients</td> <td>n (%)</td> <td>33 (46.48)</td> <td>9 (37.50)</td> <td>0.561</td> <td>12 (50.00)</td> <td>12 (52.17)</td> <td>0.772</td>	Total patients	n (%)	33 (46.48)	9 (37.50)	0.561	12 (50.00)	12 (52.17)	0.772			
WHO1n(%)40 (56.34)13 (54.17)10015 (62.50)12 (52.17)100WHO3n(%)4 (5.63)1 (4.17)1.0002 (8.33)1 (4.35)1.001Total patientsn(%)4 (6.13)0.54717 (70.83)13 (56.20)0.371Cumulative analgesic constraintsWHO1n(%)23 (32.39)8 (33.33)66 (25.00)9 (39.13)0.561WHO3n(%)3 (04.22)9 (37.50)0.56112 (50.00)9 (39.13)0.561Other patientsn(%)5 (7 (70.83)1.00018 (75.00)18 (78.26)1.000Number of patients with set to the transformation of the transformatio	Analgesic consumption afte	r dischar	ge from PAC		1						
WHO3n (%)4 (5.63)1 (4.17)1.0002 (8.33)1 (4.35)1.000Total patientsn (%)4 (61.37)1 (58.33)0.5471 (70.83)1 (3.65.2)0.371Cumulative analgesic consumativeWHO1n (%)2 3 (32.39)8 (33.33)6 (52.00)9 (39.13)0.561WHO3n (%)3 0(42.25)9 (37.50)0.5611 2 (50.00)9 (39.13)0.561Other patientsn (%)5 (7.02 (8.3)1.00018 (75.00)18 (78.26)1.000Nausean (%)5 (7.0)2 (8.3)1.0002 (8.3)1 (4.3)1.000Nausean (%)5 (7.0)2 (8.3)1.0002 (8.3)1 (4.3)1.000Nausean (%)5 (7.0)2 (8.3)1.0002 (8.3)1 (4.3)1.000Nausean (%)5 (7.0)2 (8.3)1.0002 (8.3)3 (13.0)0.666Bleedingn (%)8 (11.3)3 (12.5)1.0002 (8.3)3 (13.0)0.666Bleedingn (%)3 (4.2)2 (8.3)1.0001 (4.2)0 (0.0)1.000Chillsn (%)3 (4.2)2 (8.3)1.0001 (4.2)0 (0.0)0.0011 (4.3)Anxietyn (%)3 (4.2)2 (8.3)0.0011 (4.2)0 (0.0)0.0011 (4.3)Chillsn (%)3 (4.2)2 (8.3)0.0021 (4.3)0 (4.890 (3.10 <td>WHO1</td> <td>n (%)</td> <td>40 (56.34)</td> <td>13 (54.17)</td> <td></td> <td>15 (62.50)</td> <td>12 (52.17)</td> <td></td>	WHO1	n (%)	40 (56.34)	13 (54.17)		15 (62.50)	12 (52.17)				
Total patients         n (%)         44 (61.97)         14 (58.33)         0.547         17 (70.83)         13 (56.52)         0.371           Cumulative analgesic consumption           WHO1         n (%)         23 (32.39)         8 (33.33)         6 (25.00)         9 (39.13)         0.561           WHO3         n (%)         30 (42.25)         9 (37.50)         0.561         12 (50.00)         9 (39.13)         0.561           Total patients         n (%)         50 (42.52)         9 (37.50)         0.561         12 (50.00)         9 (39.13)         0.561           Number of patients with 35 (7 (70.83)         1 (000         18 (75.00)         18 (78.02)         16 (0.00         1000           Number of patients with 32 (2.80)         1 (4.2)         1 (000         1 (4.2)         0 (0.0)         1 (0.00           Vorning         n (%)         8 (1.3)         3 (12.5)         1 000         1 (4.2)         0 (0.0)         1 (0.00           Shivering         n (%)         8 (1.3)         3 (12.5)         1 000         1 (4.2)         0 (0.0)         1 (0.00           Childs         n (%)         1 (1.4)         0 (0.0)         -         0 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)	WHO3	n (%)	4 (5.63)	1 (4.17)	1.000	2 (8.33)	1 (4.35)	1.000			
Cumulative analgesic consurviuw         Vertication         Second	Total patients	n (%)	44 (61.97)	14 (58.33)	0.547	17 (70.83)	13 (56.52)	0.371			
WHO1         n (%)         23 (22.39)         8 (33.3)         Constrained         6 (25.00)         9 (39.13)         Constrained           WHO3         n (%)         30 (42.25)         9 (37.50)         0.561         12 (50.00)         9 (39.13)         0.561           Total patients         n (%)         5 (74.65)         17 (0.83)         1.000         18 (75.00)         18 (78.26)         1.000           Number of patients with attraction to the state	Cumulative analgesic consu	mption	1		1	1	1	1			
WH03         n (%)         30 (42.25)         9 (37.50)         0.561         12 (50.00)         9 (39.13)         0.561           Total patients         n (%)         53 (74.65)         17 (70.83)         1.000         18 (75.00)         18 (75.00)         18 (75.00)         18 (75.00)         10 (75.26)         1.000           Namber of patients with severe se	WHO1	n (%)	23 (32.39)	8 (33.33)		6 (25.00)	9 (39.13)				
Total patients         n (%)         53 (74.65)         17 (70.83)         1.000         18 (75.00)         18 (78.26)         1.000           Number of patients with at/	WHO3	n (%)	30 (42.25)	9 (37.50)	0.561	12 (50.00)	9 (39.13)	0.561			
Number of patients with adverse verse in the PACU n (%)           Nausea         n (%)         5 (7.0)         2 (8.3)         1.000         2 (8.3)         1 (4.3)         1.000           Vomiting         n (%)         2 (2.8)         1 (4.2)         0 (0.0)         1.000           Shivering         n (%)         8 (11.3)         3 (12.5)         1.000         2 (8.3)         3 (13.0)         0.666           Bleeding         n (%)         1 (1.4)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Vertigo         n (%)         3 (4.2)         2 (8.3)         1.000         1 (4.2)         0 (0.0)         1.000           Chills         n (%)         1 (1.4)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Crying         n (%)         2 (2.8)         0 (0.0)         0 (0.0)         1 (4.3)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0 (8.0)         0 (0.0)         0 (0.0)            Triedness         n (%)         1 (4.2)         0.00         0.00         0 (0.0)            Triedness         n (%)         2 (12.9.0         9 (3.5)         0.534	Total patients	n (%)	53 (74.65)	17 (70.83)	1.000	18 (75.00)	18 (78.26)	1.000			
Nausea         n (%)         5 (7.0)         2 (8.3)         1.000         2 (8.3)         1 (4.3)         1.000           Vomiting         n (%)         2 (2.8)         1 (4.2)         1.000         1 (4.2)         0 (0.0)         1.000           Shivering         n (%)         8 (11.3)         3 (12.5)         1.000         2 (8.3)         3 (13.0)         0.666           Bleeding         n (%)         1 (1.4)         0 (0.0)         -         0 (0.0)         1 (4.3)         0.489           Vertigo         n (%)         3 (4.2)         2 (8.3)         1.000         1 (4.2)         0 (0.0)         1.000           Chills         n (%)         3 (4.2)         2 (8.3)         1.000         1 (4.2)         0 (0.0)         0.00           Crying         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         -         -           Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)         -           Tiredness         n (%)         2 (2.9.6)         9 (37.5)         0.534         6 (25.0)         <	Number of patients with ad	verse eve	nts in the PA	CU n (%)	1	1	1				
Vomiting         n (%)         2 (2.8)         1 (4.2)         1.000         1 (4.2)         0 (0.0)         1.000           Shivering         n (%)         8 (11.3)         3 (12.5)         1.000         2 (8.3)         3 (13.0)         0.666           Bleeding         n (%)         1 (1.4)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Vertigo         n (%)         3 (4.2)         2 (8.3)         1.000         1 (4.2)         0 (0.0)         1.000           Chills         n (%)         2 (2.8)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Crying         n (%)         2 (2.8)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)            Total number of patients         n (%)         2 (1 (29.6)         9 (37.5)         0.534 <th< td=""><td>Nausea</td><td>n (%)</td><td>5 (7.0)</td><td>2 (8.3)</td><td>1.000</td><td>2 (8.3)</td><td>1 (4.3)</td><td>1.000</td></th<>	Nausea	n (%)	5 (7.0)	2 (8.3)	1.000	2 (8.3)	1 (4.3)	1.000			
Shivering         n (%)         8 (11.3)         3 (12.5)         1.000         2 (8.3)         3 (13.0)         0.666           Bleeding         n (%)         1 (1.4)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Vertigo         n (%)         3 (4.2)         2 (8.3)         1.000         1 (4.2)         0 (0.0)         1.000           Chills         n (%)         1 (1.4)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Crying         n (%)         2 (2.8)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)            Total number of patients         n (%)         2 (1 29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         0.111           Nausea         n (%)         2 (35.2)         8 (33.3) <t< td=""><td>Vomiting</td><td>n (%)</td><td>2 (2.8)</td><td>1 (4.2)</td><td>1.000</td><td>1 (4.2)</td><td>0 (0.0)</td><td>1.000</td></t<>	Vomiting	n (%)	2 (2.8)	1 (4.2)	1.000	1 (4.2)	0 (0.0)	1.000			
Bleeding         n (%)         1 (1.4)         0 (0.0)         -         0 (0.0)         1 (4.3)         0.489           Vertigo         n (%)         3 (4.2)         2 (8.3)         1.000         1 (4.2)         0 (0.0)         1.000           Chills         n (%)         1 (1.4)         0 (0.0)         -         0 (0.0)         1 (4.3)         0.489           Crying         n (%)         1 (1.4)         0 (0.0)         -         0 (0.0)         1 (4.3)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)         -         -           Tiredness         n (%)         1 (1.4)         0 (0.0)         1 (0.0)         1 (1.2)         0 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0)         1 (0.0) <td>Shivering</td> <td>n (%)</td> <td>8 (11.3)</td> <td>3 (12.5)</td> <td>1.000</td> <td>2 (8.3)</td> <td>3 (13.0)</td> <td>0.666</td>	Shivering	n (%)	8 (11.3)	3 (12.5)	1.000	2 (8.3)	3 (13.0)	0.666			
Vertigo         n (%)         3 (4.2)         2 (8.3)         1.000         1 (4.2)         0 (0.0)         1.000           Chills         n (%)         1 (1.4)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Crying         n (%)         2 (2.8)         0 (0.0)         0.489         2 (8.3)         0 (0.0)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         0.00         0 (0.0)         0 (0.0)            Triedness         n (%)         1 (1.4)         0 (0.0)         1.000         1 (4.2)         0 (0.0)            Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number of patients with AEs in the PACU         n (%)         25 (35.2)         8 (33.3)         0.517         11 (45.8)         6 (26.1)         0.111           Nausea         n (%)         12 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Bleeding	n (%)	1 (1.4)	0 (0.0)	-	0 (0.0)	1 (4.3)	0.489			
Chills         n (%)         1 (1.4)         0 (0.0)          0 (0.0)         1 (4.3)         0.489           Crying         n (%)         2 (2.8)         0 (0.0)         0.489         2 (8.3)         0 (0.0)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)            Tiredness         n (%)         1 (1.4)         0 (0.0)         1.000         1 (4.2)         0 (0.0)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number patients with verse verse n (werse network)         Nausea         n (%)         25 (35.2)         8 (33.3)         0.517         11 (45.8)         6 (26.1)         0.111           Vomiting         n (%)         11 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Vertigo	n (%)	3 (4.2)	2 (8.3)	1.000	1 (4.2)	0 (0.0)	1.000			
Crying         n (%)         2 (2.8)         0 (0.0)         0.489         2 (8.3)         0 (0.0)         0.489           Anxiety         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)         -           Tiredness         n (%)         1 (1.4)         0 (0.0)         1 (4.2)         0 (0.0)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number patients with verse verse n (werse verse verse n (werse verse	Chills	n (%)	1 (1.4)	0 (0.0)	-	0 (0.0)	1 (4.3)	0.489			
Anxiety         n (%)         3 (4.2)         2 (8.3)         0.489         0 (0.0)         1 (4.3)         0.489           Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)         -           Tiredness         n (%)         1 (1.4)         0 (0.0)         1 (4.2)         0 (0.0)         1 (0.0)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number of patients with Verse verse verse verse         verse verse         verse verse         verse verse         verse verse         verse verse         verse verse         verse verse verse         n (%)         2 (35.2)         8 (33.3)         0.517         11 (45.8)         6 (26.1)         0.111           Vomiting         n (%)         11 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Crying	n (%)	2 (2.8)	0 (0.0)	0.489	2 (8.3)	0 (0.0)	0.489			
Fear         n (%)         1 (1.4)         1 (4.2)         1.000         0 (0.0)         0 (0.0)            Tiredness         n (%)         1 (1.4)         0 (0.0)         1.000         1 (4.2)         0 (0.0)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (32.5)         8 (33.3)         0.517         11 (45.8)         6 (26.1)         0.111           Nausea         n (%)         11 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Anxiety	n (%)	3 (4.2)	2 (8.3)	0.489	0 (0.0)	1 (4.3)	0.489			
Tiredness         n (%)         1 (1.4)         0 (0.0)         1.000         1 (4.2)         0 (0.0)         1.000           Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number patients with Total number patients with Nausea         n (%)         25 (35.2)         8 (33.3)         0.517         11 (45.8)         6 (26.1)         0.111           Vomiting         n (%)         11 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Fear	n (%)	1 (1.4)	1 (4.2)	1.000	0 (0.0)	0 (0.0)	-			
Total number of patients with AEs in the PACU         n (%)         21 (29.6)         9 (37.5)         0.534         6 (25.0)         6 (26.1)         1.000           Total number patients with Verse vertex n (%)           Total number patients with verse vertex n (%)           Nausea         n (%)         25 (35.2)         8 (33.3)         0.517         11 (45.8)         6 (26.1)         0.111           Vomiting         n (%)         11 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Tiredness	n (%)	1 (1.4)	0 (0.0)	1.000	1 (4.2)	0 (0.0)	1.000			
Initial matrice         Image: Constraint of the second secon	Total number of patients	n (%)	21 (29.6)	9 (37.5)	0.534	6 (25.0)	6 (26.1)	1.000			
Nausea         n (%)         25 (35.2)         8 (33.3)         0.517         11 (45.8)         6 (26.1)         0.111           Vomiting         n (%)         11 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Total number nationte with	adverse	vente n (0%)					L			
In (v)         L2 (32.2)         0 (32.3)         0.317         I1 (43.6)         0 (20.1)         0.111           Vomiting         n (%)         11 (15.5)         3 (12.5)         0.139         7 (29.2)         1 (4.3)         0.018*	Nausea	n (%)	25 (35 2)	8 (33 3)	0.517	11 (45.8)	6 (26 1)	0.111			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Vomiting	n (%)	11 (15 5)	3 (12 5)	0.139	7 (29 2)	1 (4 3)	0.018#			
	Canting		11 (13.3)	. (12.5)		. (27.2)	. (10)	0.010			

			Total (n = 71)	APU (n = 24)	CON (n = 24)	ACU (n = 23)	p-value
Shivering	n (%)	13 (18.3	6 (25.0)	0.717	4 (16.7)	3 (13.0)	0.684
Flatulences	n (%)	19 (26.8)	6 (25.0)	1.000	5 (20.8)	8 (34.8)	0.489
Pyrosis	n (%)	2 (2.8)	0 (0.0)	0.457	1 (4.2)	1 (4.3)	1.000
Abdominal cramps	n (%)	3 (4.2)	2 (8.3)	0.489	0 (0.0)	1 (4.3)	1.000
Bleeding	n (%)	4 (5.6)	0 (0.0)	0.457	1 (4.2)	3 (13.0)	0.604
Vertigo	n (%)	5 (7.0)	2 (8.3)	1.000	2 (8.3)	1 (4.3)	0.603
Headache	n (%)	3 (4.2)	1 (4.2)	0.593	2 (8.3)	0 (0.0)	0.229
Hypertension	n (%)	2 (2.8)	1 (4.2)	1.000	0 (0.0)	1 (4.3)	1.000
<i>Total number of patients with AEs</i>	n (%)	47 (66.2)	16 (66.7)	1.000	17 (70.8)	14 (17.4)	0.451

**Table 4.** Acupuncture-related secondary outcomes. APU: press plaster acupressure, CON: control, ACU: press needle acupuncture, n: case number, M: median, IQR: interquartile range, STAI: State-Trait Anxiety Inventory, min<sup>-1</sup>: per minute, mmHg: millimeters of mercury, BIS: bispectral index, min: minute(s), Conc.: concentration, TCIoff: stop of target controlled infusion, WHO1 non-opioid analgesics according to the world health organization e.g. metamizol, WHO3 opioid analgesics i.e. piritramid, \*significant on an alpha level of 5% according to Kruskal-Wallis-Test, #significantly different from the CON group on an alpha level of 5%, post-hoc pairwise group comparisons were performed by Dunn's Test.

.....

acupuncture on anxiety<sup>23</sup>. A recent study showed the individualization of complementary treatments to be an important factor boosting the effect on pre-operative anxiety<sup>24</sup>. It might thus be possible -as our patients indicated overall low levels in state and trait anxiety- that the general setting, and being taken care of by the study team, helped minimising anxiety.

Furthermore, there was a trend towards lower rates of nausea and vomiting (ACU n = 6, CON n = 11) as well as less demand for strong analgesics (WHO III, ACU n = 9, CON n = 12). However, this study was not designed to evaluate the effect of acupuncture on PONV. The strong floor effect, the high rate of patients not experiencing PONV, might have masked the effect of acupuncture on PONV and post-operative analgesic consumption whose evidence is well-established<sup>9</sup>.

A particular strength of our trial is that the impact of differences in anaesthetic consumption can be ruled out. The use of TCI pumps allowed to objectively monitor the amount of applied drugs. At the time when the TCI pump was turned off, there were neither differences in regard to the estimated effect-site concentrations nor the estimated time to awakening (Table 4). In order to minimize bias from individually administered anaesthetic drugs, effect-site concentrations of anaesthetics and opioids in the TCI were set equally for all patients<sup>25</sup>. Effect-site concentrations chosen in our study were already at the lower margin of the clinically used range. Thus, an estimation of an intraoperative anaesthetic sparing effect through one of the interventions was not possible. Studies investigating the effects of acupuncture on anaesthetic consumption mainly focus on either volatile anaesthetics<sup>4</sup> or opioids<sup>5</sup> as a primary outcome.

The observed number of acupuncture-related side effects -one single event of redness at the acupuncture siteis in accordance with the assumption that acupuncture is a safe intervention<sup>26</sup>.

As variations in the effect size of acupuncture in different trials are driven predominantly by differences in treatments received by the control group rather than by differences in the characteristics of acupuncture treatment<sup>27</sup>, the number of postoperative visits, time spent with the patients, and attention was similarly offered in all groups. Thus, bias introduced by differences in patient care between study groups is unlikely and group differences observed seem rather linked to physiological mechanisms elicited by the peripheral stimulation in the intervention groups. The trend towards shorter times to extubation may be mediated by palpation upon the point GV26, as stimulated by the anesthetists' and their anesthetic teams during the awakening phase, whereas shortening the recovery time seemed to be a needling-specific effect.

#### Limitations

Limitations include the restricted sample size and limited external validity. This study was designed to detect changes in the post-operative recovery, i.e. the period between extubation and discharge from PACU, where patients are supposed to be most vulnerable. Conclusions on secondary outcomes need to be taken carefully.

Despite the use of a computer-based randomisation procedure surgery times were different between study groups. Although TCI-calculated times to awakening suggest comparability between groups, we cannot rule out, that the differences in the duration of surgery may have influenced study results. However, as indicated by the sensitivity analyses varying surgery times seem to have only marginally influenced identified group differences in recovery times.

Despite the convincing evidence that press-needles and press-plasters can neither be distinguished by patients nor by assessors<sup>12</sup>, it is not certain whether blinding was maintained throughout the study period as blinding credibility was not assessed in particular. Further bias may have resulted from the fact that the CON group could be visibly identified by assessors. This is known shortcoming studies addressing the add-on effect of acupuncture, and we are aware that placebo controls in acupuncture studies are of limited knowledge gain<sup>28</sup>. Nevertheless, the application of press-plasters as a control procedure is in line with recent suggestions, avoiding needling of the skin at non acupuncture points<sup>29</sup>, and the comparison of the ACU and APU to the CON group was necessary to quantify the effects of penetrating and non-penetrating acupuncture point stimulation.



**Figure 3.** Change in State Anxiety to baseline. The figure displays mean changes with standard error of the mean (SEM) in state anxiety (in scoring points) from baseline in the three study groups (APU: press plaster acupressure, CON: control, ACU: press needle acupuncture). Positive changes indicate an increase in state anxiety. Filled circles indicate changes in anxiety at the morning of the day of surgery. Open squares indicate changes in anxiety prior to the induction anaesthesia, i.e. placement of the oxygen mask. P-Values are given for the comparison between all three groups according to analysis of variance (ANOVA; marked with #) and posthoc pairwise comparisons at the induction of anaesthesia as performed by unpaired t-Test.





Figure 4. Surgery times. Extreme values were identified from the graphical display of individual surgery times per group.

As reported previously<sup>11</sup>, the point selection included points that had been described to reduce anxiety, promote awakening, and reduce pain and anaesthesia-related symptoms such as PONV. The decision was made on the basis of existing evidence (e.g. PC6 and PONV)<sup>9</sup>, expert opinion, and tradition. The use of press needles turned out to be feasible even in the peri-operative setting, and the chosen points seemed appropriate to address proposed indications. However, it is debateable, if acupuncture applied with common acupuncture needles resulting in higher stimulation intensity could cause larger treatment effects. The impact of needling depth, needle diameter and stimulation intensity on acupuncture effects are still under debate, but expert consensus suggests that larger treatment effects are achieved by deep and strong needling stimuli<sup>30</sup>. In addition, other point regimens might be equally effective<sup>31</sup>. Further, our results are limited to a group of women receiving laparoscopic surgery, and can therefore not simply be extrapolated to other patient groups. However, we show the possibility to implement well-designed acupuncture research in a standard setting and encourage to do so for other indications as well.

#### Conclusions

This study shows for the first time that acupuncture can shorten the time from extubation to 'ready for discharge' from the PACU in gynaecological laparoscopy. Further effects of acupuncture on secondary outcomes of recovery, i.e. shorter time to extubation (awakening) and reduced incidence of vomiting, need to be carefully interpreted. As recovery is a core process goal of surgery, multidisciplinary evidence-based programs can be encouraged to consider acupuncture as an element in gynaecological laparoscopy.

#### References

- Lambertz, R. et al. Perioperative management of transthoracic oesophagectomies: Fundamentals of interdisciplinary care and new approaches to accelerated recovery after surgery. Der Anaesthesist 65, 458–466, https://doi.org/10.1007/s00101-016-0179-y (2016).
- Kehlet, H. Multimodal approach to postoperative recovery. Current opinion in critical care 15, 355–358, https://doi.org/10.1097/ MCC.0b013e32832fbbe7 (2009).
   Deters D. Maurine D. M. Schwarz, D. A. Commutational to determine the second determine the second
- Dexter, F., Macario, A., Manberg, P. J. & Lubarsky, D. A. Computer simulation to determine how rapid anesthetic recovery protocols to decrease the time for emergence or increase the phase I postanesthesia care unit bypass rate affect staffing of an ambulatory surgery center. *Anesth Analg* 88, 1053–1063 (1999).
- Lu, Z., Dong, H., Wang, Q. & Xiong, L. Perioperative acupuncture modulation: more than anaesthesia. Br J Anaesth 115, 183–193, https://doi.org/10.1093/bja/aev227 (2015).
- Sun, Y., Gan, T. J., Dubose, J. W. & Habib, A. S. Acupuncture and related techniques for postoperative pain: a systematic review of randomized controlled trials. *Br J Anaesth* 101, 151–160, https://doi.org/10.1093/bja/aen146 (2008).
- Usichenko, T. I., Lehmann, C. & Ernst, E. Auricular acupuncture for postoperative pain control: a systematic review of randomised clinical trials. *Anaesthesia* 63, 1343–1348, https://doi.org/10.1111/j.1365-2044.2008.05632.x (2008).
- Wu, M. S. *et al.* The Efficacy of Acupuncture in Post-Operative Pain Management: A Systematic Review and Meta-Analysis. *PloS one* 11, e0150367, https://doi.org/10.1371/journal.pone.0150367 (2016).
- Asmussen, S. et al. Meta-Analysis of Electroacupuncture in Cardiac Anesthesia and Intensive Care. Journal of intensive care medicine, 885066617708558, https://doi.org/10.1177/0885066617708558 (2017).
- Lee, A., Chan, S. K. & Fan, L. T. Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 11, CD003281, https://doi.org/10.1002/14651858.CD003281.pub4 (2015).
- Gan, T. J. et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 118, 85–113, https:// doi.org/10.1213/ANE.00000000000002 (2014).
- 11. Fleckenstein, J. *et al.* Acupuncture for post anaesthetic recovery and postoperative pain: study protocol for a randomised controlled trial. *Trials* **15**, 292, https://doi.org/10.1186/1745-6215-15-292 (2014).
- Miyazaki, S., Hagihara, A., Kanda, R., Mukaino, Y. & Nobutomo, K. Applicability of press needles to a double-blind trial: a randomized, double-blind, placebo-controlled trial. *Clin J Pain* 25, 438–444, https://doi.org/10.1097/AJP.0b013e318193a6e1 (2009).
- Amjad, N. & Fazal, A. Mini cholecystectomy now a day stay surgery: anaesthetic management with multi modal analgesia. JPMA. The Journal of the Pakistan Medical Association 52, 291–296 (2002).
- Dewinter, G. B. et al. Systemic Lidocaine Fails to Improve Postoperative Pain, But Reduces Time to Discharge Readiness in Patients Undergoing Laparoscopic Sterilization in Day-Case Surgery: A Double-Blind, Randomized, Placebo-Controlled Trial. Regional anesthesia and pain medicine 41, 362–367, https://doi.org/10.1097/AAP.00000000000398 (2016).
- Goe, A. et al. Epinephrine or Gv-26 Electrical Stimulation Reduces Inhalant Anesthestic Recovery Time in Common Snapping Turtles (Chelydra Serpentina). Journal of zoo and wildlife medicine: official publication of the American Association of Zoo Veterinarians 47, 501–507, https://doi.org/10.1638/2015-0264.1 (2016).
- 16. Hsu, C. H. *et al.* Shock resuscitation with acupuncture: case report. *Emerg Med J* 23, e18, https://doi.org/10.1136/emj.2004.023218 (2006).
- 17. Aldrete, J. A. & Kroulik, D. A postanesthetic recovery score. Anesth Analg 49, 924-934 (1970).
- Chung, F., Chan, V. W. & Ong, D. A post-anesthetic discharge scoring system for home readiness after ambulatory surgery. J Clin Anesth 7, 500–506, doi:0952-8180(95)00130-A (1995).
- Zhao, Z. Q. Neural mechanism underlying acupuncture analgesia. Progress in neurobiology 85, 355–375, https://doi.org/10.1016/j. pneurobio.2008.05.004 (2008).
- Kim, K. H., Kim, D. H., Kim, H. Y. & Son, G. M. Acupuncture for recovery after surgery in patients undergoing colorectal cancer resection: a systematic review and meta-analysis. *Acupunct Med* 34, 248–256, https://doi.org/10.1136/acupmed-2015-010941 (2016).
- Gemma, M. et al. Acupuncture accelerates recovery after general anesthesia: a prospective randomized controlled trial. Journal of integrative medicine 13, 99–104, https://doi.org/10.1016/S2095-4964(15)60159-5 (2015).
- Chang, C. L., Lee, J. C., Tseng, C. C., Chang, Y. H. & Cheng, J. T. Decrease of anesthetics activity by electroacupuncture on Jen-Chung point in rabbits. *Neuroscience letters* 202, 93–96 (1995).
- Wang, S. M., Peloquin, C. & Kain, Z. N. The use of auricular acupuncture to reduce preoperative anxiety. Anesth Analg 93, 1178–1180, table of contents (2001).
- Attias, S. et al. Effectiveness of integrating individualized and generic complementary medicine treatments with standard care versus standard care alone for reducing preoperative anxiety. J Clin Anesth 29, 54–64, https://doi.org/10.1016/j.jclinane.2015.10.017 (2016).
- Gambus, P. L. & Troconiz, I. F. Pharmacokinetic-pharmacodynamic modelling in anaesthesia. Br J Clin Pharmacol 79, 72–84, https://doi.org/10.1111/bcp.12286 (2015).
- Witt, C. M. *et al.* Safety of acupuncture: results of a prospective observational study with 229,230 patients and introduction of a medical information and consent form. *Forsch Komplementmed* 16, 91–97, https://doi.org/10.1159/000209315 (2009).
- Vickers, A. J. et al. Acupuncture for Chronic Pain: Update of an Individual Patient Data Meta-Analysis. The journal of pain: official journal of the American Pain Society 19, 455–474, https://doi.org/10.1016/j.jpain.2017.11.005 (2018).
- Irnich, D., Salih, N., Offenbacher, M. & Fleckenstein, J. Is sham laser a valid control for acupuncture trials? *Evid Based Complement Alternat Med* 2011, 485945, https://doi.org/10.1093/ecam/neq009 (2011).
- MacPherson, H. et al. Influence of control group on effect size in trials of acupuncture for chronic pain: a secondary analysis of an individual patient data meta-analysis. PloS one 9, e93739, https://doi.org/10.1371/journal.pone.0093739 (2014).
- Choi, Y. J., Lee, J. E., Moon, W. K. & Cho, S. H. Does the effect of acupuncture depend on needling sensation and manipulation? Complementary therapies in medicine 21, 207–214, https://doi.org/10.1016/j.ctim.2012.12.009 (2013).
- Cheong, K. B., Zhang, J. P., Huang, Y. & Zhang, Z. J. He Effectiveness of Acupuncture in Prevention and Treatment of Postoperative Nausea and Vomiting - A Systematic Review and Meta-Analysis. *PloS one* 8, e82474, https://doi.org/10.1371/journal.pone.0082474 (2013).

### Acknowledgements

Parts of the study constitute the topics of the medical thesis of Caroline Gurschler. This investigator-initiated trial was realized through a grant received from SEIRIN<sup>®</sup>. The IIT agreement assured that only investigators were responsible for study conception, design, operational execution, data handling and analysis and that interpretation, reporting and publication of trial results were at their discretion.

#### **Author Contributions**

J.F. conception and design, funding, data collection, manuscript writing and final approval of the manuscript. P.B. conception and design, data collection, manuscript writing and final approval of the manuscript. C.G. design, data collection and final approval of the manuscript. T.W. data acquisition, critical revision and final approval of the manuscript. T.G. conception and design, critical revision and final approval of the manuscript. D.I. conception and design, financial support, manuscript writing, final approval of manuscript. All authors read and approved the final manuscript.

#### **Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-33459-y.

**Competing Interests:** D.I., J.F. and P.B. receive honorarium and travel costs from non-profit academic organizations, physician Chambers and universities for teaching and lecturing. T.A. received research grants sponsored by CytoSorbens, Pulsion, Köhler Chemie and the non-profit Centre of Integrated Oncology Köln-Bonn (CIO). T.W., T.G. and C.G. declare to have no conflict of interest.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018